Red Flags Detected
- Going Concern (worsened) — Going-concern language persists despite extended cash runway; substantial doubt remains about ability to continue operations beyond Q1 2027 without additional capital.
- Material Weakness (improved) — Material weaknesses in internal controls remediated as of December 31, 2024 and remain effective through December 31, 2025.
Theriva cuts 32% of workforce, out-licenses SYN-020, extends cash runway to Q1 2027
Filed March 12, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 6, 2025 · ~2 min read
Key Changes
-
high
Company implemented 32% workforce reduction (7 employees) in September 2025, incurring $520K severance to focus on VCN-01 development and business development. Expected to save $1.8M annually but signals capital preservation mode.
Business: Workforce reduction verify on EDGAR → -
high
VIRAGE Phase 2b trial showed VCN-01 plus chemotherapy improved median overall survival to 10.8 vs 8.6 months (p=0.0546), with statistically significant PFS improvement (7.0 vs 4.6 months, p=0.0105). EMA endorsed multi-dose Phase 3 design.
Business: VIRAGE results verify on EDGAR → -
high
Out-licensed SYN-020 to Rasayana for $300K upfront plus potential $38M in milestones and low-to-mid single-digit royalties. Rasayana assumes all development costs, freeing capital for oncology focus.
Business: SYN-020 license verify on EDGAR →
2 more material changes plus the full narrative summary — create a free account to see the rest. Takes 30 seconds.
Partner
Trade TOVX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Generated by AI · Jun 8, 2026 7:55 PM